Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 30 - Sep 4
The product information provided on this site is providefor general information purposes only and it is not intended as a substitutefor the actual approved product information
) 4149 (Springer, 2010)
Reputable suppliers use appropriate packaging to maintain temperature stability
Researched applications In the published preclinical and clinical literature the effects of Cagrilintide are documented in the following areas: Obesity (stand-alone) , Phase 2 data (Lau 2021, 10.8 % at 4.5 mg) Obesity + Semaglutide (CagriSema) , Phase 3 REDEFINE 1 (25.3 %) T2DM + obesity , Phase 3 REDEFINE 2 Cardiovascular prevention , Phase 3 REDEFINE 3 (n ~ 7000) MASLD/MASH , exploratory in Phase 2 Type 2 diabetes (monotherapy) , preclinical data Prediabetes , exploratory plans Science & studies 4.1 Key publications Lau D.C.W., Erichsen L., Francisco A.M., et al
